Compare AMPH & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMPH | NBTX |
|---|---|---|
| Founded | 1996 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2014 | 2020 |
| Metric | AMPH | NBTX |
|---|---|---|
| Price | $26.02 | $21.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $31.00 | $8.00 |
| AVG Volume (30 Days) | ★ 360.6K | 37.9K |
| Earning Date | 02-26-2026 | 09-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.27 | N/A |
| Revenue | ★ $723,305,000.00 | $11,930,711.00 |
| Revenue This Year | $1.35 | N/A |
| Revenue Next Year | $5.10 | $145.24 |
| P/E Ratio | $12.23 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $20.39 | $2.85 |
| 52 Week High | $39.01 | $30.35 |
| Indicator | AMPH | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.32 | 49.72 |
| Support Level | $27.31 | $19.61 |
| Resistance Level | $29.52 | $21.68 |
| Average True Range (ATR) | 1.05 | 1.08 |
| MACD | -0.01 | -0.09 |
| Stochastic Oscillator | 4.53 | 43.46 |
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.